Drug Profile
Olanzapine - Eli Lilly and Company
Alternative Names: LY 170053; LY-170052; Midax; Olanzapine controlled-release; Olanzapine LAI; Olanzapine long-acting; Olanzapine pamoate; Zypadhera; Zyprexa; Zyprexa Relprevv; Zyprexa Velotab; Zyprexa ZydisLatest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Oxazepines; Small molecules; Thiazepines
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Aggression; Bipolar depression; Bipolar disorders; Manic episodes; Schizophrenia
- No development reported Anorexia nervosa; Huntington's disease; Major depressive disorder; Personality disorders
Most Recent Events
- 19 Mar 2024 Teva Branded Pharmaceutical Products plans a phase I trial for schizophrenia or schizoaffective Disorder in March 2024 (IM, Injection) (NCT06319170)
- 07 Jan 2024 NDR batch #30: No updates; kept NDR as it is as trial completed in 2016 and Dev line is NDR from 2021 but as drug was in phase III development and no any source for discontinuation found hence not marked as discontinued mail sent to the company for confirmation
- 21 Apr 2023 Cheplapharm acquires olanzapine from Eli Lilly